Biomea Fusion
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biomea Fusion sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Biomea Fusion: 9 sponsored US clinical trials, 3 recruiting.
Biomea Fusion sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 1 trials.
Top-decile sponsor footprint
Biomea Fusion ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
NCT07502495
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
NCT07223216
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
NCT05918692
Food Effect Study in Healthy Volunteers
NCT07254286
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
NCT06152042
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT05631574
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
NCT05731544
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Biomea Fusion pipeline
3 recruiting of 9 indexed (33% open); 2 completed (22%).
Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biomea Fusion: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Biomea Fusion sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Biomea Fusion page
9 registered trials is a research-attention snapshot, not an endorsement of Biomea Fusion or any single study.
- 3 of Biomea Fusion's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Biomea Fusion studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biomea Fusion pipeline card: 9 registered trials from official public datasets.Report a data error.